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Abstract
Introduction: No previous study has investigated sexual functioning in prediabetic women. This study was aimed at investigating sexual 
function in young women with various types of prediabetes.
Material and methods: The study included four groups of women: women with isolated impaired fasting glucose (Group A; n = 19), 
isolated impaired glucose tolerance (Group B; n = 18), presence of both impaired fasting glucose and impaired glucose tolerance (Group 
C; n = 18), as well as matched healthy controls (Group D; n = 19). All participants completed questionnaires evaluating sexual function 
(Female Sexual Function Index — FSFI) and the presence and severity of depressive symptoms (Beck Depression Inventory-Second Edi-
tion — BDI-II).
Results: The total FSFI and BDI-II scores were lower in Group C than in the remaining groups of women, while the total FSFI score was 
lower in Groups A and B than in Group D. Patients with both impaired fasting glucose and impaired glucose tolerance had lower scores 
in all domains (sexual desire, arousal, lubrication, orgasm, sexual satisfaction, and dyspareunia). Compared to Group D, Group A was 
characterised by lower domain scores for sexual desire and sexual satisfaction, and Group B by lower domain scores for desire, arousal, 
and orgasm. In all groups of prediabetic women, the overall FSFI score correlated negatively with the degree of insulin resistance and 
weakly with the total BDI-II score.
Conclusions: Impaired fasting glucose and impaired glucose tolerance may disturb sexual functioning and induce depressive symptoms.
(Endokrynol Pol 2018; 69 (2): 175–181)
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Streszczenie
Wstęp: W poprzednich badaniach nie oceniano funkcjonowania seksualnego kobiet ze stanem przedcukrzycowym.
Badanie miało na celu ocenę funkcji seksualnych u młodych kobiet z różnymi typami stanu przedcukrzycowego.
Materiał i metody: Badanie objęło cztery grupy kobiet: kobiety z izolowaną nieprawidłową glikemią na czczo (grupa A, n = 19), izolowaną 
upośledzoną tolerancją glukozy (grupa B, n = 18), występowaniem zarówno nieprawidłowej glikemii na czczo i upośledzonej tolerancji 
glukozy (grupa C, n = 18) oraz zdrowe kobiety (grupa D, n = 19). Wszystkie uczestniczki badania wypełniły kwestionariusze oceniające 
funkcje seksualne (Indeks Funkcji Seksualnych Kobiet — FSFI) oraz obecność i nasilenie objawów depresyjnych (Beck Depression Inven-
tory-Second Edition — BDI-II).
Wyniki: Całkowite wartości skal FSFI i BDI-II były niższe w grupie C niż w pozostałych grupach kobiet, podczas gdy całkowita punk-
tacja FSFI był niższa w grupach A i B niż w grupie D. Pacjentki z nieprawidłową glikemią na czczo i zaburzeniami tolerancji glukozy 
miały niższe wyniki we wszystkich podskalach (pożądanie seksualne, pobudzenie seksualne, lubrykacja, orgazm, satysfakcja seksualna 
i dyspareunia). W porównaniu z grupą D, grupa A charakteryzowała się niższymi wynikami w domenach dla pożądania seksualnego 
i satysfakcji seksualnej, podczas gdy grupa B miała niższe wyniki w domenach dla pożądania, pobudzenia seksualnego i orgazmu. We 
wszystkich grupach kobiet ze stanem przedcukrzycowym ogólny wynik FSFI korelował negatywnie ze stopniem insulinooporności 
i słabo z całkowitym wynikiem skali BDI-II.
Wnioski: Nieprawidłowa glikemia na czczo i upośledzona tolerancja glukozy mogą zaburzać funkcjonowanie seksualne i wywołać objawy 
depresyjne. (Endokrynol Pol 2018; 69 (2): 175–181)
Słowa kluczowe: objawy depresyjne, nieprawidłowa glikemia na czczo, upośledzenie tolerancji glukozy, funkcjonowanie seksualne
Introduction
From a pathophysiological and prognostic point of 
view, impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT), although classified together as 
prediabetes, are metabolically distinct disorders, with 
only a limited overlap [1–4]. Subjects with IGT have 
marked muscle insulin resistance with less pronounced 
hepatic insulin resistance, while subjects with IFG 
have severe hepatic insulin resistance with normal or 
Assoc. Prof. Agnieszka Drosdzol-Cop, MD, PhD, Chair of Woman’s Health, Medical University of Silesia, ul. Medyków 12; 40–752 Katowice, 
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near-normal muscle insulin sensitivity [3]. Both IFG 
and IGT are characterised by a reduction in early-phase 
insulin secretion, while subjects with IGT also have im-
paired late-phase insulin secretion [3]. After adjusting 
for hypertension and dyslipidaemia, only IGT remains 
an independent risk factor of cardiovascular events or 
death [1]. Moreover, the association between IGT and 
diabetes development is better demonstrated than for 
IFG. In an analysis of six prospective studies, the risk 
of developing diabetes was found to be approximately 
3.6% to 8.7% per year in patients with IGT [5]. A study of 
1245 Italian telephone company employees carried out 
for 11.5 years found that, unlike baseline IGT, baseline 
IFG did not predict progression to diabetes mellitus [6].
It seems that the presence of glucose homeostasis 
disorders may impair female sexual functioning. Sexual 
dysfunction was observed in most studies including 
women with type 2 diabetes [7–10], in whom the relative 
risk of sexual dysfunction is estimated at 2.29 [11]. Moreo-
ver, most [12–14], but not all [15], studies revealed that the 
prevalence of sexual dysfunction was higher in women 
with metabolic syndrome than age-matched healthy 
controls. However, these studies have serious limitations. 
Some of them included postmenopausal women [12, 15] 
and they did not investigate a relationship between the 
type of glucose metabolism impairment and female sexual 
function. Therefore, the aim of the present study was 
to compare sexual function and depressive symptoms 
between patients with various types of prediabetes.
Materials and methods
Study population
The study population consisted of 55 women (aged 
25–45 years) with recently diagnosed and previously 
untreated prediabetes, who were recruited among 
subjects with a familial history of type 2 diabetes, body 
mass index above 25 kg/m2, or previous gestational 
diabetes. On the basis of fasting and 2-h postchallenge 
plasma glucose, prediabetic patients were allocated 
into one of the three groups: women with isolated IFG 
(Group A; n = 19) (fasting plasma glucose at least 100 
mg/dL but less than 126 mg/dL, and plasma glucose 
concentration two hours after a 75-g oral glucose load 
less than 140 mg/dL); women with isolated IGT (fast-
ing plasma glucose less than 100 mg/dL, and a 2-h 
postchallenge glucose level at least 140 mg/dL but less 
than 200 mg/dL) (Group B; n = 18); and women with 
concomitant IFG and IGT (IFG + IGT) (fasting plasma 
glucose at least 100 mg/dL but less than 126 mg/dL, and 
a 75-g oral glucose load between 140 and 200 mg/dL) 
(Group C; n = 18). Prediabetic patients were compared 
with 19 age- and weight-matched control subjects with 
normal glucose tolerance (fasting plasma glucose level 
less than 100 mg/dL and a 2-h postchallenge glucose 
level less than 140 mg/dL) (Group D; n = 19). Subjects 
were excluded if they met at least one of the following 
criteria: diabetes, hyperprolactinaemia, hypogonadism, 
thyroid disorders, polycystic ovary syndrome, impaired 
renal or hepatic function, psychiatric problems, post-
partum complications, and developmental or acquired 
anomalies of the female reproductive system. We also 
excluded women with a history of urogynaecological 
operations that could affect sexual function, pregnant 
or breastfeeding women, sexually inactive women, as 
well as women receiving any treatment. All participants 
were informed of the study aims and provided written 
consent before entering the study, which was further 
approved by the local Ethics Committee.
Methods
Venous blood samples were collected from the antecubi-
tal vein at 8 a.m. after an overnight 12-h fasting. Plasma 
glucose, plasma lipids (total cholesterol, LDL choles-
terol, HDL cholesterol, and triglycerides) and serum 
insulin were assayed by routine laboratory techniques 
using commercially available kits (Roche Diagnostics, 
Basel, Switzerland; DRG Instruments GmbH, Marburg, 
Germany). LDL-cholesterol levels were measured 
directly. Moreover, glucose levels were measured 2 h 
after oral ingestion of 75 g of glucose. The homeostasis 
model 1 for insulin resistance index (HOMA1-IR) was 
calculated as [fasting plasma glucose (mg/dL) × fasting 
plasma insulin (μU/mL)/405].
Immediately after blood collection, all women 
considered for enrolment were asked to complete 
a questionnaire assessing their demographic character-
istics, smoking, physical activity, education, occupation, 
stress exposure, general health, number and duration 
of marriages, number of sexual partners, deliveries, 
and abortions. Moreover, the participants completed 
questionnaires evaluating their sexual functioning 
and depressive symptoms. At the time of filling in the 
questionnaires, neither the subjects nor the investiga-
tors were aware of the biochemical results. Although 
all potential participants completed the questionnaires, 
only data of women with IFG and/or IGT and data of 
control women were included in the final analyses. 
The female sexual function index (FSFI), used in our 
study, evaluates all phases of the female sexual cycle, 
sexual satisfaction, and dyspareunia in the last four 
weeks [16–18]. This 19-item questionnaire includes six 
domains: sexual desire (items 1 and 2), sexual arousal 
(items 3–6), lubrication (items 7–10), orgasm (items 
11–13), satisfaction (items 14–16), and pain (items 
17–19). FSFI items are scored on a 0–5 or 1–5 scale, 
with 0 indicating no sexual activity. Scores for each of 
the six domains were calculated by adding individual 
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domain question scores and multiplying by the domain 
factor (0.6 for desire, 0.3 for arousal and lubrication, and 
0.4 for orgasm, satisfaction, and pain). The total FSFI 
score, which is the sum of the scores for all individual 
domains, may range from 2.0 to 36.0. Higher scores in-
dicate better sexual function, and a total FSFI score less 
than 26.55 is suggestive of sexual dysfunction [16–18].
The presence and severity of depressive symptoms 
were measured with the Beck Depression Inventory 
Second Edition (BDI-II), consisting of 21 items and be-
ing a valid and reliable measure of depressive state [19]. 
These items are adjusted to measure depressive symp-
toms corresponding with the diagnostic criteria for 
depressive disorders outlined in the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition [20]. 
Each item is rated on a four-point Likert scale from 0 (not 
present) to 3 (severe). The total score, being a sum of the 
item scores, may range from 0 to 63. The BDI-II score 
of 0–13 was categorised ‘minimal’, 14–19 ‘mild’, 20–28 
‘moderate severe’, and 29–63 ‘severe’ depression [19].
Statistical analysis
Kolmogorov-Smirnov test was used to assess the distri-
bution of variables. Quantitative data without a normal 
distribution were natural log-transformed to normalise 
their distributions prior to statistical analysis. Study 
groups were compared using analysis of covariance fol-
lowed by Bonferroni post hoc tests after consideration 
of age, smoking, body mass index, waist circumference, 
marital status, education, occupational activity, type of 
work, profession, physical activity, stress exposure, and 
blood pressure as potential confounders. The χ2 test was 
used for all qualitative variables. Correlations were calcu-
lated using Pearson’s r-tests. Differences were described 
as statistically significant if p values were less than 0.05.
Results
General characteristics of the study groups
There were no differences between the groups in terms 
of age, body mass index, eating disorders, smoking 
(number of cigarettes and duration of smoking), physi-
cal activity, education, occupational activity, type of 
work performed, stress exposure, number of sexual 
partners, number and duration of marriages, number 
of deliveries, as well as in systolic and diastolic blood 
pressure (Table I). Expectedly, fasting plasma glucose 
levels were higher in Groups A and C than in Groups 
B and D, while 2-h postchallenge plasma glucose levels 
were higher in Groups B and C than in Groups A and 
D. All groups of women with prediabetes had higher 
levels of triglycerides, higher HOMA1-IR and lower 
levels of HDL cholesterol than women with normal 
glucose tolerance (Table I).
Assessment of sexual function
The mean total FSFI score was lower in women with 
IFG + IGT than in the remaining groups of women, 
as well as lower in Groups A and B than in Group D. 
Sexual dysfunction was diagnosed in five women (26%) 
from Group A, five women (28%) from Group B, eight 
women (44%) from Group C, as well as in two women 
(11%) from Group D (Table II). Compared to Group D, 
Group A was characterised by lower domain scores for 
sexual desire and sexual satisfaction, Group B by lower 
domain scores for sexual desire, arousal, and orgasm, 
while Group C by lower scores for all domains. The 
mean domain score for desire was higher in group C 
than in Group A and Group B, while the mean score 
for satisfaction was higher in Group C than in Group B 
(Table II).
Assessment of depressive symptoms
The total BDI-II score, as well as the percentage of 
women with total and mild depressive symptoms, 
differed between women with IFG + IGT and the 
remaining groups of participants (Table III). Moreover, 
the BDI-II score was insignificantly higher in women 
with isolated IFG (p = 0.062) and isolated IGT (p = 0.057) 
than in control subjects (Table III).
In all studied groups, the mean total FSFI score 
negatively correlated with the total BDI-II score (Group 
A: r = –0.40 [p < 0.001]; Group B: r = –0.38 [p < 0.001]; 
Group C: r = –0.43 [p < 0.001]; Group D: r = –0.34 
[p < 0.01]) and with HOMA1-IR (Group A: r = –0.35 
[p < 0.01]; Group B: r = –0.37 [p < 0.01]; Group C: 
r = –0.41 [p < 0.001]; Group D: r = –0.29 [p < 0.05]). In all 
groups of patients, the BDI-II score correlated with body 
mass index (Group A: r = 0.42 [p < 0.001]; Group B: 
r = 0.47 [p < 0.001]; Group C: r = 0.44 [p < 0.001]; Group 
D: r = 0.51 [p < 0.001]). In women with isolated IFG, there 
were negative correlations between HOMA1-IR and sexual 
desire (r = –0.48 [p < 0.001]), and between HOMA1-IR 
and sexual satisfaction (r = –0.35 [p < 0.01]). Women 
with isolated IGT showed a negative correlation between 
HOMA1-IR and sexual desire (r = –0.52 [p < 0.001]), sexual 
arousal (r = –0.29 [p < 0.05]), and orgasm (r = –0.32 
[p < 0.01]). In IFG + IGT patients, HOMA1-IR negatively 
correlated with all domain scores (r values between –0.30 
[p < 0.05] for dyspareunia and –0.49 [p < 0.001] for desire). 
No other correlations were significant.
Discussion
The present study shows, for the first time, that dis-
turbances in female sexual functioning may occur in 
women with even mild abnormalities of glucose home-
ostasis, which is accompanied by depressive symptoms. 
Moreover, individual dimensions of sexual functioning 
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Table I. Sociodemographic characteristics, plasma lipids, and glucose homeostasis markers in the study population
Tabela I. Charakterystyka socjodemograficzna, lipidy osocza i markery homeostazy glukozy w populacji badanej
Group A1 Group B2 Group C3 Group D4
Number of patients 19 18 18 19
Age [years; mean (SD)] 35 (5) 36 (5) 37 (5) 35 (6)
Body mass index [kg/m2; mean (SD)] 29.5 (3.2) 29.8 (3.5) 30.2 (4.0) 28.9 (4.2)
Smokers (%)/Number of cigarettes a day [n; mean (SD)]/
Duration of smoking [months, mean (SD)]
37/12 (5)/115 (55) 39/11 (6)/120 (52) 44/14(7)/123 (48) 42/12 (6)/110 (47)
Physical activity: total/once a week/several times a week/ 
/once a month (%)
58/21/16/21 56/22/11/22 50/22/6/22 53/21/11/21
Primary or vocational/secondary/university education (%) 21/32/47 22/39/39 28/28/44 26/32/42
Occupational activity/Blue-collar/white-collar/pink-collar 
workers (%)
74/21/21/32 72/17/17/39 72/22/11/39 68/21/16/32
Number of sexual partners [n; mean (SD)] 2.1 (0.6) 1.9 (0.8) 2.3 (0.8) 1.7 (0.8)
Number of marriages [n; mean (SD)]/ duration of marriages 
[months; mean (SD)]
1.2 (0.6)/71 (25) 1.1 (0.6)/53(28) 1.0 (0.5)/83 (29) 0.9 (0.5)/80 (28)
Number of deliveries [n; mean (SD)]/ Number of abortions 
[n; mean (SD)]
1.9 (0.8)/0.4 (0.4) 1.8 (0.6)/0.4 (0.4) 1.6 (0.7)/0.4 (0.3) 1.7 (0.6)/0.2 (0.3)
Stress exposure (%) 84 78 83 79
Systolic blood pressure [mmHg; mean (SD)] 132 (14) 135 (12) 136 (11) 131 (15)
Diastolic blood pressure [mmHg; mean (SD)] 84 (8) 85 (8) 86 (7) 83 (8)
Fasting glucose [mg/dL; mean (SD)] 112 (6)d, f 89 (5) 115 (5)d, f 86 (8)
2-h post-glucose load plasma glucose  
[mg/dL; mean (SD)]
124 (10) 168 (15)b, f 175 (12)b, f 118 (10)
HOMA1-IR [mean (SD)] 4.4 (1.6)f 4.6 (1.4)f 6.0 (1.7)a, c, f 2.0 (0.6)
Total cholesterol [mg/dL; mean (SD)] 230 (24) 239 (28) 245 (32) 240 (30)
LDL cholesterol [mg/dL; mean (SD)] 132 (15) 138 (14) 143 (18) 137 (11)
HDL cholesterol [mg/dL; mean (SD)] 45 (10)e 43 (10)e 42 (11)e 55 (11)
Triglycerides [mg/dL; mean (SD)] 235 (40)e 243 (46)e 256 (50)e 204 (46)
SD — standard deviation
1women with isolated impaired fasting glucose; 2women with isolated impaired glucose tolerance; 3women with both impaired fasting glucose and impaired glucose 
tolerance; 4control women with normal glucose tolerance
ap < 0.05, bp < 0.001 vs. Group A; cp < 0.05, dp < 0.001 vs. Group B; ep < 0.05, fp < 0.001 vs. Group D
Table II. Sexual functioning in women with prediabetes
Tabela II. Funkcjonowanie seksualne kobiet ze stanem przedcukrzycowym
Variable Group A1 Group B2 Group C3 Group D4
FSFI score [mean (SD)] 29.73 (2.80)d 29.63 (2.65)d 26.80 (2.86)a, c, f 32.97 (3.05)
FSFI score ≤ 26.55 (%) 26d 28d 44a, c, e 11
Sexual desire [mean (SD)] 4.86 (0.60)e 4.70 (0.59)e 4.07 (0.65)b, c, f 5.67 (0.61)
Sexual arousal [mean (SD)] 5.02 (0.69) 4.75 (0.64)e 4.45 (0.72)f 5.56 (0.63)
Lubrication [mean (SD)] 5.12 (0.73) 5.40 (0.54) 4.64 (0.79)d 5.45 (0.58)
Orgasm [mean (SD)] 4.88 (0.83) 4.57 (0.65)e 4.36 (0.49)f 5.44 (0.66)
Sexual satisfaction [mean (SD)] 4.76 (0.55)e 5.17 (0.62) 4.31 (0.76)c, e 5.38 (0.45)
Dyspareunia [mean (SD)] 5.09 (0.46) 5.04 (0.37) 4.97 (0.35)d 5.47 (0.49)
SD — standard deviation
1women with isolated impaired fasting glucose; 2women with isolated impaired glucose tolerance; 3women with both impaired fasting glucose and impaired glucose 
tolerance; 4control women with normal glucose tolerance
ap < 0.05, bp < 0.01 vs. Group A; cp < 0.05 vs. Group B; dp < 0.05, ep < 0.01, fp < 0.001 vs. Group D
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are affected in a prediabetes type-dependent manner. 
The decrease in FSFI was most pronounced in women 
with the concomitant presence of IFG and IGT, less 
expressed in women with isolated IGT, and mildest 
in isolated IFG. On the basis of the obtained results, it 
seems that concomitant presence of both IFG and IGT 
is associated with a greater risk of sexual dysfunction 
and of depressive symptoms, making subjects with 
this type of prediabetes particularly prone to the ear-
lier development and faster progression of impaired 
sexual functioning and depressive symptoms. Pre-
diabetic states usually remain asymptomatic and are 
diagnosed either incidentally or, as in the case of our 
study, by screening of patients at high diabetes risk. In 
the light of our research, it seems reasonable to assume 
that premenopausal women with sexual dysfunction, 
which is not a consequence of another disorder or treat-
ment, should be evaluated for the presence of fasting 
or postprandial hyperglycaemia.
The obtained results suggest that sexual dysfunction 
in all groups of our patients was in part a consequence 
of insulin resistance. The severity of sexual dysfunction 
correlated with HOMA1-IR and — also to a lesser extent 
— with plasma triglycerides and HDL cholesterol, ab-
normal levels of which are characteristic for atherogenic 
dyslipidaemia, which is commonly found in subjects 
with impaired insulin sensitivity [21]. However, the 
fact that these correlations were at most moderate and 
there was no relationship between body mass index and 
sexual function suggests that other mechanisms, not 
investigated by our research group, are also responsible 
for the observed changes. In our previous studies, IFG 
or IGT increased secretion of proinflammatory cytokines 
from human monocytes and lymphocytes, and induced 
low-grade systemic inflammation and a procoagulant 
state [22–25]. Taking into account the complex proathero-
genic action of all these cytokines [26, 27], an important 
role of monocytes and T lymphocytes [28, 29], low-grade 
inflammation [30], as well as enhanced coagulation and 
diminished fibrinolysis at various stages of atherogenesis 
[31], all these changes may contribute to an increased 
risk of the development and progression of atheroscle-
rosis in prediabetic subjects. Interestingly, in line with 
this hypothesis, patients with the concomitant presence 
of both IFG or IGT were characterised by higher mono-
cyte release of tumour necrosis factor-α, interleukin-1β, 
interleukin-6, and monocyte chemoattractant protein-1, 
as well as by higher plasma levels of high-sensitivity 
C-reactive protein than subjects with the presence of 
IFG alone or IGT alone [23]. Moreover, compared to 
lymphocytes from IFG subjects, phytohemagglutinin-
activated T cells from IFG patients produced larger 
amounts of interleukin-2, interferon-γ, and tumour 
necrosis factor-α [22], which may explain why impair-
ment in orgasm was observed in women with IGT, but 
not in women with IFG.
Another possible explanation for sexual dysfunc-
tion in women with IFG and/or IGT is an association 
between adverse glucose metabolism and neuropathy. 
Hyperglycaemia, dyslipidaemia and the metabolic syn-
drome, found in the participants of our study, as well as 
microvascular disease, not determined in our study but 
observed relatively commonly in prediabetic patients 
[32], are regarded as causative factors of peripheral 
and/autonomic neuropathy. Although generally milder 
in comparison to diabetes, neuropathy occurs more 
frequently in prediabetic patients than in the general 
population and mainly affects small fibres mediating 
sensory function. Finally, impaired sexual function 
may result from abnormal production of hormones, 
playing a role in the regulation of sexual cycle, sexual 
satisfaction, and pain. These hormones include testos-
terone, dehydroepiandrosterone and prolactin because 
disorders associated with their increased production are 
often accompanied by glucose metabolism disorders, 
while metformin, known to reduce glucose levels and 
to inhibit progression of IGT to diabetes [33], decreased 
circulating levels of these hormones [34–38].
Table III. Depressive symptoms in premenopausal women with prediabetes
Tabela III. Objawy depresyjne u kobiet ze stanem przedcukrzycowym przed menopauzą
Variable Group A1 Group B2 Group C3 Group D4
BDI-II score [mean (SD)] 10.4 (3.7) 10.7 (3.5) 14.2 (2.5)a, b, d 7.8 (3.4)
depressive symptoms [n (%)] 4 (21) 5 (28) 10 (56)a, b, c 2 (11)
mild symptoms [n (%)] 4 (21) 4 (22) 9 (50)a, b, c 2 (11)
moderate symptoms [n (%)] 0 (0) 1 (6) 1 (6) 0 (0)
severe symptoms [n (%)] 0 (0) 0 (0) 0 (0) 0 (0)
SD — standard deviation
1women with isolated impaired fasting glucose; 2women with isolated impaired glucose tolerance; 3women with both impaired fasting glucose and impaired glucose 
tolerance; 4control women with normal glucose tolerance
ap < 0.05 vs. Group A; bp < 0.05 vs. Group B; cp < 0.01, dp < 0.001 vs. Group D
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Among all domains of FSFI, particular attention 
should be given to sexual desire. Impaired desire was 
the only sexual dysfunction observed in all groups 
of women with prediabetes. There were statistically 
significant differences in desire between women with 
both IFG and IGT and women with IFG alone or IGT 
alone. Moreover, correlations between HOMA1-IR and 
desire were stronger than correlations between insulin 
resistance and arousal, lubrication, orgasm, satisfaction, 
and pain. Interestingly, in our recent study, only sexual 
desire was disturbed in young women with macropro-
lactinaemia, which contrasted with multidimensional 
impairment of sexual function in women with elevated 
monomeric prolactin, probably because the amount of 
monomeric prolactin released locally from macroprolac-
tin complexes is lower than that found in patients with 
monomeric hyperprolactinaemia [39]. Furthermore, 
apart from arousal, only desire was disturbed among 
all groups of women with thyroid disease: women with 
euthyroid Hashimoto’s thyroiditis, non-autoimmune 
hypothyroidism, and autoimmune thyroid hypofunc-
tion [40]. All these findings taken together suggest that 
desire may be particularly susceptible to even small 
changes in metabolism or hormone balance.
Contrary to sexual dysfunction, depressive symp-
toms were observed exclusively in women with both 
IFG and IGT, and this finding was in disagreement with 
the presence of correlations between the total FSFI and 
BDI-II scores in all study groups. This means that, apart 
from impaired sexual functioning, worsened mood is 
also related to other conditions. One of these includes 
eating disorders, particularly obesity or overweight, 
found in many participants of our study because the 
BDI-II score correlated with body mass index. This 
association probably results from body dissatisfaction 
and low self-esteem associated with obesity or being 
overweight, and/or from a negative perception of 
eating disorders by society. Alternatively, depressive 
symptoms may be associated with a proinflammatory 
state. In agreement with this explanation, monocyte 
release of tumour necrosis factor-α, interleukin-1β, in-
terleukin-6, and monocyte chemoattractant protein-1, 
which are postulated to play a role in the development 
of depression [41], was higher in IGF + IGT patients 
than in patients with either IFG or IGT alone [23]. The 
study protocol does not allow us to conclude whether, 
in the studied subpopulations of subjects with pre-
diabetes, depressive symptoms are a consequence or 
a causative factor for sexual dysfunction. 
Our study has several limitations that should be 
considered. Although well-validated, the utility of FSFI 
and BDI-II questionnaires is limited by their subjecti-
vity. All groups of patients included a small number 
of patients, and therefore it cannot be excluded that 
larger groups would ensure significant differences 
in other domains. Because current pharmacotherapy 
belonged to the exclusion criteria, sexual functioning 
may differ in subjects receiving hypoglycaemic and/or 
hypolipidaemic agents. Finally, although oral glucose 
tolerance test has poor repeat-test reproducibility, we 
measured fasting and 2-h postchallenge plasma glucose 
only once [42]. This strategy allowed us to minimise 
the possibility that the participants were aware of their 
clinical state but decreased the precision of assessment 
of glucose homeostasis.
Conclusions
To sum up, the results of our study demonstrate that 
prediabetic women are characterised by disturbances 
in sexual functioning, the extent of which depends on 
the type of glucose metabolism abnormality. Sexual 
dysfunction is particularly pronounced in women with 
the concomitant presence of IGF and IGT and may be 
causatively linked to depressive symptoms.
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